Best of 2023: PMR: glad or bad tidings? Please don’t tell your patient that PMR “typically” lasts two years. According to real-world data from the UK, one in four patients with PMR is prescribed steroids by their primary care physician for over four years. But nobody tells them this at the start, and that causes big problems later on ..read more

Best of 2023: New ACR RA-ILD Treatment Guidelines – What Were They Smoking!? Rheumatoid arthritis related interstitial lung disease (RA-ILD) is common, with symptomatic RA-ILD affecting approximately 8% of RA patients. There is a very limited evidence base supporting treatment and therefore the recent release of ACR guidelines is to be welcomed. However, the published guidelines appear discordant with the best available evidence base.  ..read more

RheumNow recently highlighted a publication that reported about a third of physicians in academia intend to leave. To our colleagues in non-academic situations, this may seem incredibly high. I think an important contributor to the intention to leave academics is that something that used to be a benefit has now become a challenge: namely, teaching ..read more

..read more

Please don’t tell your patient that PMR “typically” lasts two years. According to real-world data from the UK, one in four patients with PMR is prescribed steroids by their primary care physician for over four years. But nobody tells them this at the start, and that causes big problems later on ..read more

Frailty in PMR: Why do I need to care? It is important to clarify that frailty is not a synonym of age (chronological age). Although there are only a few studies studying the impact of frailty in PMR, frailty is a relevant issue due to several important factors ..read more

IL-6 Inhibitors in PMR: Give early or late? It's exciting to be able to have this conversation because it's only in the past year that we have an approved non-corticosteroid therapy for PMR that's been shown to be effective in a well done clinical trial ..read more

What Goes Wrong with the Immune System in PMR? Kornelis van der Geest, MD, PhD Polymyalgia rheumatica (PMR) is a common inflammatory rheumatic disease. The exact trigger for PMR onset remains unknown. However, immunology studies and clinical trials with biological DMARDs now shed light on the immune pathways involved in PMR ..read more

Aatke van der Maas, MD, PhD Treatment of PMR is still largely based on glucocorticoids. Where in other inflammatory rheumatic disorders, such as RA and PsA, early initiation of methotrexate is common practice, this is not the case in PMR.  ..read more

Unpopular opinion: spinach can be bad for you PMR might be one of the most rewarding diagnoses to make in real practice: the patient comes to you in severe debilitating pain, and you prescribe steroids, giving them their lives back! As much as this impressive response makes your intervention appear almost magical, there is the often-forgotten story about the implications of such a diagnosis and treatment on patients' daily lives.  ..read more